TheraCryf Announces Significant Shareholding Change

The latest update is out from Evgen Pharma ( (GB:TCF) ).

TheraCryf plc announced that Northern Standard Limited, a company in which Non-Executive Director Ed Wardle holds a 49% interest, now owns 422,727,272 ordinary shares of TheraCryf, representing 19.67% of the company’s ordinary shares. This transfer, which took place on May 21, 2025, from Tracarta Limited, signifies a significant shift in shareholding structure, potentially impacting the company’s governance and stakeholder dynamics.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company based in Alderley Park, Cheshire, focusing on oncology and neuropsychiatry. It has a diverse clinical and preclinical pipeline targeting conditions such as glioblastoma, neurodevelopmental disorders, addiction, anxiety, and narcolepsy. The company aims to develop compelling data sets for preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and is listed on AIM in London under the ticker symbol TCF.

Average Trading Volume: 3,996,669

Technical Sentiment Signal: Sell

Current Market Cap: £5.05M

See more data about TCF stock on TipRanks’ Stock Analysis page.